Skip to main content
. 2019 Nov 28;50:421–432. doi: 10.1016/j.ebiom.2019.11.006

Fig 6.

Fig 6

Allergen-specific cytokine responses of cultured PBMCs from patients treated with BM32 (n = 25) or placebo (n = 10). (A–F) Shown are the levels (y-axes, pg/ml) of (A) IL-4, (B) IL-5 (C) IL-13, (D) IFN-γ, (E) IL-10 and (F) IL-17 produced by cultured PBMCs at different time points of the study (x-axes) in response to a mix of recombinant Phl p 1, 2, 5 and 6. Dots (Placebo: red circles, BM32: blue squares) represent individual patients and lines represent the means. Differences between BM32-treated and placebo group are indicated. (* = p < .05 and n.s. = not significant).